KOSPI large cap
GC Biopharma
A leading Korean pharma centered on blood products and vaccines. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
006280.KS Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-58.2%'22-25.6%'23-15.1%'24+28.8%'25+19.5%YTD-24.5%
Money in ▸·
GC Biopharma~₩1.7T
▸ Money out·
Financials & Segments
- Total revenue · ~₩1.7T (FY2024)
- Segments · Blood products · Vaccines · Prescription and consumer healthcare
Revenue from
No refined links yet.
Pays to
No refined links yet.